In this free webinar, gain insight into the FDA's perspective on model-informed drug development (MIDD). Attendees will learn about pharmacokinetic/pharmacodynamic (PK/PD) modeling strategies and their benefits. The featured speakers will discuss the application of PK/PD modeling and simulation across different drug development pathways.
TORONTO, July 3, 2025 /PRNewswire-±¬ÁϹ«Éçapp/ -- With strong support and encouragement from the FDA in recent years, model-informed drug development (MIDD) has become a pivotal strategy for enhancing the efficiency and cost-effectiveness of clinical trials.1 MIDD approaches help balance the risks and benefits of drug products in development using a variety of quantitative methods, including pharmacokinetic/pharmacodynamic (PK/PD) modeling.
PK/PD modeling leverages mathematical models to describe the relationship between drug dose, concentration in bodily fluids, drug effect and time based on nonclinical and clinical data sources in drug development. By utilizing PK/PD modeling and simulation, drug developers can answer a variety of scientific questions, for example how to optimize dosing regimens, adjust dosing in special populations and assess factors that drive the variability in drug response among individuals. Overall, this strategy enables sponsors to increase the likelihood of study success and guide personalized therapy.
In this webinar, the featured speakers provide a brief overview of PK/PD modeling, highlight the advantages of using PK/PD modeling and simulation in drug development and present case studies that demonstrate how MIDD strategies supported key decision-making and streamlining of 505(b)(2) and 505(b)(1) drug development programs.
Register for this webinar to learn how PK/PD modeling can drive smarter decision-making, support regulatory alignment and enhance the efficiency of drug development programs.
Join experts from , Agnieszka Marcinowicz, PhD, Director, Clinical Pharmacology; Isaac Asante, PhD, Principal Scientist, Pharmacology; and Jayesh Patel, Principal Scientist, Pharmacokinetics, for the on Thursday, July 24, 2025, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit
Reference:
1. Lesko, L.J. and van der Graaf, P.H. (2024), Reflections on Model-Informed Drug Development. Clin Pharmacol Ther, 116: 267-270.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit
For information about hosting a webinar visit
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected],
SOURCE Xtalks
Share this article